Seismyc DETECT. DECODE. TRADE. LIVE
← All stories
Markets 1 sources

Lilly looks beyond obesity with $2.88B autoimmune buyout

Covered by 1 source · 1 article

The maker of Mounjaro and Zepbound just signed its 13th deal of the year.

Covered by
Thestreet

All coverage

Lilly looks beyond obesity with $2.88B autoimmune buyout
TheStreet 1h ago

Lilly looks beyond obesity with $2.88B autoimmune buyout

The maker of Mounjaro and Zepbound just signed its 13th deal of the year.